San Diego-based Arcturus Therapeutics Ltd. announced that the company was reassuming 100 percent of its global rights from Germany-based CureVac AG for ARCT-810, a messenger RNA (mRNA) drug to treat OTC deficiency.
Aradigm’s inhaled antibiotic fails late-stage study
Anthrax, Antibiotics, Bioterrorism, Bioterrorism Infections, Clinical Trials, Cystic Fibrosis, Fast Track Designation, Health, Inhaled Tularemia, Lung Infections, Melioidosis, Non-Cystic Fibrosis Bronchiectasis (non-CF BE), Orphan Drugs, Pneumonic Plague, Q fever, R&D, Shares, SmokingAradigm Corp.’s inhaled antibiotic for a rare, incurable disorder affecting the lungs failed a late-stage study, sending the company’s shares down in premarket trading.